Pediatric Blood & Cancer, 1545-5017

Journal

More filtering options
  1. 1989
  2. Radio-iodobenzylguanidine scintigraphy of neuroblastoma: conflicting results, when compared with standard investigations

    Kjeld Schmiegelow, Martti A Simes, Lone Agertoft, Gunilla Berglund, Ingebjörn Storm-Mathisen, Michael Andreassen, Toivo T Salmi, Randi Nygard, Thomas Wiebe, Anders Kreuger & Salah Hayder, 1989, In: Medical and Pediatric Oncology. 17, 2, p. 126-130

    Research output: Contribution to journalArticle

  3. 1990
  4. Letter to the editor: "Role of chemotherapy in pediatric pulmonary blastoma" by Ozkaynak et al., 1990

    Albert Békássy, Inga Hägerstrand, Henrik Henrikson, Stanislaw Garwicz & Thomas Wiebe, 1990, In: Medical and Pediatric Oncology. 18, 5, p. 359-359

    Research output: Contribution to journalLetter

  5. Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells

    Albert Békássy, Jan Liliemark, Stanislaw Garwicz, Thomas Wiebe, Hans Gulliksson & Curt Peterson, 1990, In: Medical and Pediatric Oncology. 18, 2, p. 136-142

    Research output: Contribution to journalArticle

  6. 1992
  7. Hepatocellular carcinoma associated with arteriohepatic dysplasia in a 4-year-old girl

    Albert Békássy, Stanislaw Garwicz, Thomas Wiebe, Inga Hägerstrand & Ove A Jensen, 1992, In: Medical and Pediatric Oncology. 20, 1, p. 78-83

    Research output: Contribution to journalArticle

  8. 1997
  9. Letter to the editor: Uncertain role of high dose chemotherapy with autologous stem cell support in pediatric pleuro-pulmonary blastoma (PPB)

    Albert Békássy, Stanislaw Garwicz, Thomas Wiebe & Inga Hägerstrand, 1997, In: Medical and Pediatric Oncology. 28, 1, p. 75-76

    Research output: Contribution to journalLetter

  10. 1999
  11. Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome?

    Carl-Magnus Kullendorff, Fredrik Mertens, M Donner, Thomas Wiebe, Måns Åkerman & Nils Mandahl, 1999, In: Medical and Pediatric Oncology. 32, 2, p. 79-83

    Research output: Contribution to journalArticle

  12. Dosimetry and growth hormone deficiency following cranial irradiation of childhood brain tumors

    Marianne Schmiegelow, Sören Lassen, Lars Weber, Hans Skovgaard-Poulsen, Henrik Hertz & Joern Müller, 1999, In: Medical and Pediatric Oncology. 33, 6, p. 564-571

    Research output: Contribution to journalArticle

  13. 2000
  14. 2002
  15. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: Multi-institutional collaborative study

    BM Frost, S Eksborg, O Bjork, J Abrahamsson, M Behrendtz, Anders Castor, E Forestier & G Lonnerholm, 2002, In: Medical and Pediatric Oncology. 38, 5, p. 329-337

    Research output: Contribution to journalArticle

  16. 2004
  17. Childhood cancer: the family experience

    M B Björk & Inger Hallström, 2004, In: Pediatric Blood & Cancer. 43, 4, p. 336

    Research output: Contribution to journalPublished meeting abstract

  18. Parents’ and children’s involvement in decision-making during hospitalisation

    Inger Hallström, 2004, In: Pediatric Blood & Cancer. 43, p. 307

    Research output: Contribution to journalPublished meeting abstract

  19. 2005
  20. Children with cancer and their families – a longitudinal approach

    Maria Björk, Thomas Wiebe & Inger Hallström, 2005, In: Pediatric Blood & Cancer. 45, p. 562-563 2 p.

    Research output: Contribution to journalPublished meeting abstract

  21. Development of an international pediatric oncology research network

    Roberta Woodgate, Juanne Clarke, Faith Gibson, Inger Hallström, Nancy Kline, Leanne Monterosso, Louise von Essen & Lena Wettergren, 2005, In: Pediatric Blood & Cancer. 45, 4, p. 400

    Research output: Contribution to journalPublished meeting abstract

  22. Immunosuppression with ALG and CsA is first line treatment in children with SAA lacking an HLA identical sibling.

    Albert Békássy, Anna Locasciulli, Judith C W Marsh, Gerard Socié, Monika Fuehrer & Jakob Passweg, 2005, In: Pediatric Blood & Cancer. 45, 3, p. 359-360

    Research output: Contribution to journalLetter

  23. Needs of children with cancer during their initial hospitalization

    Maria Björk, Berit Nordström & Inger Hallström, 2005, In: Pediatric Blood & Cancer. 45, 4, p. 564

    Research output: Contribution to journalArticle

  24. Needs of young children with cancer during their initial hospitalization.

    Maria Björk, Berit Nordström & Inger Hallström, 2005, In: Pediatric Blood & Cancer. 45, 4, p. 564

    Research output: Contribution to journalPublished meeting abstract

  25. 2006
  26. Development of a disease-specific quality of life questionnaire for children & adolescents with idiopathic thrombocytopenic purpura (ITP-QoL)

    S. von Mackensen, Cecilia Nilsson, M. Jankovic, N. Mirra, E. D'Angelo, A. Borkhardt & Rolf Ljung, 2006, In: Pediatric Blood & Cancer. 47, Suppl.5, p. 688-691

    Research output: Contribution to journalArticle

  27. Studies of chronic ITP in children and adolescents.

    Cecilia Nilsson, Ulf Tedgård & Rolf Ljung, 2006, In: Pediatric Blood & Cancer. 47, S5, p. 660-661

    Research output: Contribution to journalArticle

  28. 2007
  29. Mortality experiences among 15+ year survivors of childhood and adolescence cancers.

    Torgil Möller & Stanislaw Garwicz, 2007, In: Pediatric Blood & Cancer. 48, 3, p. 363-363

    Research output: Contribution to journalLetter

  30. Successful treatment of a child with t(15;19)-positive tumor.

    Fredrik Mertens, Thomas Wiebe, Catharina Adlercreutz, Nils Mandahl & Christopher A French, 2007, In: Pediatric Blood & Cancer. 49, p. 1015-1017

    Research output: Contribution to journalArticle

  31. 2008
  32. Experiences and needs of children with cancer and their families in a longitudinal perspective

    Maria Björk, Thomas Wiebe & Inger Hallström, 2008, In: Pediatric Blood & Cancer. 49, 4: Suppl, p. 557

    Research output: Contribution to journalPublished meeting abstract

  33. 2009
  34. Biomarkers in the Cerebrospinal Fluid and Neurodegeneration in Langerhans Cell Histiocytosis

    Desiree Gavhed, Selma Olsson Akefeldt, Gustaf Osterlundh, Evaldas Laurencikas, Lars Hjorth, Kaj Blennow, Lars Rosengren & Jan-Inge Henter, 2009, In: Pediatric Blood & Cancer. 53, 7, p. 1264-1270

    Research output: Contribution to journalArticle

  35. Health Status at Long-Term Follow-Up in Patients Treated for Extremity Localized Ewing Sarcoma or Osteosarcoma: A Scandinavian Sarcoma Group Study

    L. H. Aksnes, H. C. F. Bauer, A. A. Dahl, S. D. Fossa, Lars Hjorth, N. Jebsen, H. Lernedal & K. Sundby Hall, 2009, In: Pediatric Blood & Cancer. 53, 1, p. 84-89

    Research output: Contribution to journalArticle

  36. Individualized 6-Mercaptopurine Increments During Consolidation Treatment Of Lower Risk Childhood All

    Thomas Frandsen, Jonas Abrahamsson, Birgitte Lausen, Kim Vettenranta, Mats Heyman, Mikael Behrentz, Anders Castor & Kjeld Schmiegelow, 2009, In: Pediatric Blood & Cancer. 53, 5, p. 726-727

    Research output: Contribution to journalPublished meeting abstract

  37. Low frequency of EWSR1 rearrangements in neoplasms classified as high-risk wilms tumors.

    Ildiko Frigyesi, Emely Möller, Ylva Stewénius, Margareth Isaksson, Johannes Bras, Jan Alumets, Ingrid Øra, Bengt Sandstedt & David Gisselsson Nord, 2009, In: Pediatric Blood & Cancer. 53, p. 683-684

    Research output: Contribution to journalArticle

Previous 1 2 3 Next